Verbatim response from Claude
This is a fast-changing area, so here's an honest breakdown:
Current Situation (as of early 2025)
The FDA declared the semaglutide shortage over, which triggered enforcement against most compounded versions. The landscape shifted significantly.
Services Still Operating (with caveats)
Hims & Hers - Pivoted to offering personalized/combination compounds, though facing ongoing legal challenges
Empower Pharmacy / Strive Pharmacy - Compounding pharmacies that some telehealth services still partner with, arguing "503B" exemptions
Henry - Has been navigating this space, worth checking current offerings
Mochi Health - Has offered alternatives while adapting to regulations
Important Honest Caveats
- Availability changes weekly - what's offered today may not be tomorrow
- Legal gray areas remain - some services are operating under active litigation
- 503A vs 503B distinctions matter legally but are complex
- Tirzepatide (Mounjaro) shortage status differs from semaglutide, so some compounded options may still be more clearly legal
My Recommendation
Check GoodRx or Wisp for current comparisons, and verify directly with any service before subscribing, as their offerings are genuinely in flux.
Would you like help thinking through alternatives like manufacturer patient assistance programs?